Yahoo

Edwards solidifies TAVR dominance in long-term trial readout

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...
Nasdaq

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Medscape

TAVR Comparable to Surgery at 6 Years in Low-Risk Patients, but Reinterventions Increase

Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but the reintervention was higher in the TAVR arm.
Orange County Business Journal

FDA Clears New Indication for Edwards’ Sapien 3

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...
Medical Xpress

FDA approves SAPIEN 3 platform for asymptomatic severe aortic stenosis

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without ...
Yahoo

Edwards’ request for broader TAVR Medicare coverage gets pushback

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...
Seeking Alpha

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the ...
Healio

TAVR for asymptomatic severe aortic stenosis superior to surveillance regardless of age

Please provide your email address to receive an email when new articles are posted on . The benefit of TAVR vs. clinical surveillance for patients with asymptomatic severe aortic stenosis did not vary ...
MD&M East

Back at It Again: Edwards Obtains Another Approval

The approvals keep rolling in for Edwards Lifesciences. The Irvine, CA-based company said it has won a nod from FDA to approve the Sapien 3 platform, a transcatheter aortic valve replacement therapy ...
News Medical

UTHealth researchers examine effectiveness of Sapien 3 TAVR in low-risk patients with aortic stenosis

The Structural Heart Program team at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) is among the first in the country to investigate the safety and ...
Seeking Alpha

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...